JUN 06, 2021 5:02 PM PDT

New drug reduces tumor size in lung cancer patients with KRAS gene mutation

The most recent results from the CODEBREAK 100 phase 2 clinical trial support the use of the drug sotorasib to reduce tumor size in lung cancer patients with a specific mutation in the KRAS gene. The results were presented late last week at the American Society of Clinical Oncology (ASCO) annual meeting following publication in the New England Journal of Medicine.

The KRAS gene is responsible for encoding a protein that regulates growth. The researchers pinpointed a specific KRAS mutant protein called p.G12C that occurs in about 13% of people diagnosed with lung cancer. In the presence of this mutation, the KRAS protein is permanently in the "on" mode", meaning cells don’t stop multiplying and develop into tumors.

In the United States alone, over 200,000 people receive lung cancer diagnoses every year. The urgency to find a treatment that targets the KRAS mutation could not be greater, given that many patients become resistant to other forms of treatment. Sotorasib is a drug developed by Amgen Inc. It was tested in the CODEBREAK 100 phase 2 clinical trial in 126 patients with non-small-cell lung cancer and KRAS mutation.

The clinical trial’s findings showed that 37.1% of patients in the study saw their tumors shrink by at least 30%. Additionally, approximately 82% of those who received the daily oral dose of sotorasib experienced some slowing of tumor growth.

"The excitement surrounding this trial result is that sotorasib, just approved for clinical use, becomes the first targeted therapy for lung cancer patients with KRAS mutations," says co-corresponding study author Vamsidhar Velcheti, MD, associate professor of Medicine at NYU Grossman of Medicine, and director of thoracic medical oncology at Perlmutter Cancer Center. "KRAS-targeted treatments, decades in the making, are urgently needed for these patients with limited therapeutic options."

"Sotorasib showed clinically significant benefit without any new safety concerns in patients with this specific form of KRAS mutant lung cancer," adds co-corresponding author Ramaswamy Govindan MD, the Anheuser Busch Chair in Medicine at Washington University School of Medicine. "Moving forward, our team will seek to inform the development of combination therapies featuring sotorasib and other emerging drugs, and to determine which best fit the mix of mutations in each patient's cancer cells."

Sources: New England Journal of Medicine, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
AUG 19, 2021
Cancer
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
AUG 19, 2021
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
Colorectal cancer (CRC) is the third most diagnosed type of cancer in both men and women in the United States and CRC in ...
OCT 10, 2021
Cell & Molecular Biology
DNA Can Reveal Treatments for Lung Cancer in 'Never-Smoked' Patients
OCT 10, 2021
DNA Can Reveal Treatments for Lung Cancer in 'Never-Smoked' Patients
There is a well-known causal connection between smoking and lung cancer, and most research on lung cancer has been focus ...
NOV 09, 2021
Immunology
Wikipedia, but Make It Immune Cells
NOV 09, 2021
Wikipedia, but Make It Immune Cells
Scientists have established the first searchable database of complex immune data, providing the foundations for a new er ...
NOV 15, 2021
Cancer
Dogs Get Cancer Too
NOV 15, 2021
Dogs Get Cancer Too
“Cancer” isn’t a word anyone wants to hear from their doctor. However, many dog owners may not conside ...
NOV 14, 2021
Genetics & Genomics
Cancer Drug Target Could Actually Worsen Disease
NOV 14, 2021
Cancer Drug Target Could Actually Worsen Disease
Cancer drugs have been developed that target an enzyme, Shp2. But that enzyme has a more complex role than we knew.
NOV 18, 2021
Immunology
Ultrasound Helps Shuttle Cancer-Killing Antibodies to the Brain
NOV 18, 2021
Ultrasound Helps Shuttle Cancer-Killing Antibodies to the Brain
Antibody therapies harness the immune system's power to fight a broad spectrum of diseases, from cancer to infectiou ...
Loading Comments...